 |
|
|
|
|
30-June-2009:
Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company’s oral selective antagonist of the DP2 (also known as CRTH2) receptor. <more>
15-June-2009:
Amira Pharmaceuticals, Inc. announced today that it will present preclinical data from its LPA1 receptor antagonist program on June 30, 2009 at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona.<more>
20-April-2009:
Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist. Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD. <more>
|
1-July-2009:
Amira Pharmaceuticals’ Experimental Lung Disease Drug May Have Legs - Xconomy < LINK>
30-June-2009:
Amira Pharmaceuticals Can Breathe Easier After Mouse Study - Xconomy <LINK>
18-May-2009:
Clinician's Roundtable | In the Wake of 9/11: Research in Pulmonary Fibrosis - ReachMD XM Radio
4-May-2009:
Focus on Allergy | Coming Soon: More Targeted Oral Asthma Therapies - ReachMD XM Radio
|
Founded in 2005; $28 million invested; five novel lead compounds discovered.
Download our fact sheet for an overview of Amira. PDF
Keep pace with developments at Amira by signing up for regular email
alerts. Sign up here.
|
